In a significant portfolio move, Steve Cohen's Point72 Asset Management completely exited its stake in Supernus Pharmaceuticals (SUPN), selling all 1.32 million shares. The position was previously valued at approximately $68.16 million.
This trade occurred during the second quarter of 2026, which ended on June 30, and was disclosed in a regulatory 13F filing on August 14. These filings reveal past activity and do not represent real-time trades. Shortly after the trading period, on August 3, Supernus announced an all-stock merger with Indivior Pharmaceuticals and reported mixed Q2 financial results, which included a revenue beat but a significant GAAP loss per share. [4, 5, 8]